

Ultrasonographic Assessment of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

Nahla Abass Mohamed Hassan¹, Eiman Hassan Kamal^{2*}, Maisa Elzaki^{3,4}, Ala M.A. Elgyoum⁵

¹Department of Medical Diagnostic Ultrasound, Al-Zaiem Al-Azhari University, Sudan

²Department of Medical Imaging, Al-Zaiem Al-Azhari University, Sudan

³Faculty of Radiological Sciences and Medical Imaging, Alzaiem Alazhari University, Khartoum, Sudan

⁴Department of Diagnostic Radiology, College of Applied Medical Sciences, Taibah University, Al-Madinah-Al-Munawara, Medina, Saudi Arabia

⁵Faculty of Radiology and Nuclear Medicine Sciences, The National Ribat University, Khartoum, 11111, Sudan

DOI: <https://doi.org/10.36347/sjmcr.2026.v14i03.025>

| Received: 25.12.2025 | Accepted: 01.02.2026 | Published: 18.03.2026

*Corresponding author: Eiman Hassan Kamal

Department of Medical Imaging, Al-Zaiem Al-Azhari University, Sudan

Abstract

Original Research Article

Background: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide and is strongly associated with type 2 diabetes mellitus (T2DM). **Objective:** To evaluate ultrasonographic features of NAFLD in patients with T2DM and examine their association with clinical and metabolic parameters. **Methods:** A descriptive cross-sectional study was conducted on 100 patients with T2DM. Abdominal ultrasonography was performed using a 3.5-MHz curvilinear transducer to assess liver echogenicity, echo texture, and liver size. **Results:** Moderate hepatic steatosis was the most frequent finding (39%) and showed statistically significant associations with older age, higher body weight, increased liver size, and longer duration of diabetes ($p < 0.001$). **Conclusion:** Ultrasonography provides a reliable and accessible modality for early detection and risk stratification of NAFLD in patients with T2DM.

Keywords: Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ultrasonography.

Copyright © 2026 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) represents a hepatic manifestation of metabolic syndrome and is highly prevalent among patients with type 2 diabetes mellitus (T2DM). The coexistence of NAFLD and T2DM accelerates disease progression and increases the risk of cardiovascular and liver-related morbidity.

MATERIALS AND METHODS

This cross-sectional study was conducted at Al-Mak Nimr Hospital, Nile River State. A total of 100 patients with confirmed T2DM were enrolled. All participants underwent abdominal ultrasonography after at least six hours of fasting using a 3.5-MHz curvilinear transducer.




Figure 1. Distribution of liver echogenicity grades among patients with type 2 diabetes mellitus.

RESULTS

Moderate hepatic steatosis was identified in 39% of patients, followed by mild steatosis in 35% and

normal echogenicity in 26%. Increasing liver echogenicity was significantly associated with advancing age, higher body weight, larger liver size, and longer duration of diabetes mellitus ($p < 0.001$).




Figure 2. Relationship between liver echogenicity grades and duration of diabetes mellitus.

DISCUSSION

This study demonstrates a high prevalence of NAFLD among patients with T2DM, consistent with previous international reports. The significant association between liver echogenicity and duration of diabetes highlights the cumulative impact of chronic metabolic dysfunction.

STRENGTHS AND LIMITATIONS

Strengths include standardized ultrasonographic assessment and evaluation of multiple clinical parameters.

Limitations include the single-center design and cross-sectional nature of the study.

CONCLUSION

NAFLD is highly prevalent among patients with T2DM. Routine ultrasonographic screening may facilitate early detection and improved clinical management.

REFERENCES

- Abdullah, A., Hassan, R., Ahmed, M. and Osman, S. (2024) 'Association between body mass index

- and non-alcoholic fatty liver disease assessed by FibroScan', *Journal of Clinical Imaging Science*, 14(2), pp. 85–92.
- Adams, L.A., Anstee, Q.M., Tilg, H. and Targher, G. (2017) 'Non-alcoholic fatty liver disease and its relationship with cardiovascular disease', *Nature Reviews Gastroenterology & Hepatology*, 14(9), pp. 528–544.
 - Ahmed, M.H. and Byrne, C.D. (2007) 'Non-alcoholic fatty liver disease: What is the role of imaging?', *World Journal of Gastroenterology*, 13(31), pp. 4211–4219.
 - Ali, R., Khan, M.A., Hussain, S. and Farooq, U. (2020) 'Ultrasonographic grading of fatty liver disease and its correlation with body mass index', *Journal of Ultrasound in Medicine*, 39(3), pp. 545–552.
 - Angulo, P. (2002) 'Nonalcoholic fatty liver disease', *New England Journal of Medicine*, 346(16), pp. 1221–1231.
 - Ballestri, S., Lonardo, A., Romagnoli, D. and Loria, P. (2015) 'Ultrasonographic fatty liver indicator and metabolic risk', *World Journal of Gastroenterology*, 21(40), pp. 11529–11539.
 - Bedossa, P. (2017) 'Pathology of non-alcoholic fatty liver disease', *Liver International*, 37(S1), pp. 85–89.
 - Brunt, E.M., Wong, V.W., Nobili, V., *et al.*, (2015) 'Nonalcoholic fatty liver disease', *Nature Reviews Disease Primers*, 1, pp. 15080.
 - Byrne, C.D. and Targher, G. (2015) 'NAFLD: A multisystem disease', *Journal of Hepatology*, 62(1), pp. S47–S64.
 - Chalasani, N., Younossi, Z., Lavine, J.E., *et al.*, (2018) 'The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance', *Hepatology*, 67(1), pp. 328–357.
 - Cusi, K. (2012) 'Role of insulin resistance and lipotoxicity in non-alcoholic fatty liver disease', *Gastroenterology*, 142(4), pp. 711–725.
 - Eslam, M., Newsome, P.N., Sarin, S.K., *et al.*, (2020) 'A new definition for metabolic associated fatty liver disease', *Journal of Hepatology*, 73(1), pp. 202–209.
 - Fracanzani, A.L., Valenti, L., Bugianesi, E., *et al.*, (2008) 'Risk of severe liver disease in NAFLD', *Hepatology*, 48(3), pp. 792–798.
 - Hernaez, R., Lazo, M., Bonekamp, S., *et al.*, (2011) 'Diagnostic accuracy of ultrasonography for fatty liver', *Hepatology*, 54(3), pp. 1082–1090.
 - Lee, S.S. and Park, S.H. (2014) 'Radiologic evaluation of non-alcoholic fatty liver disease', *World Journal of Gastroenterology*, 20(23), pp. 7392–7402.
 - Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. and Loria, P. (2015) 'Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome', *Digestive and Liver Disease*, 47(3), pp. 181–190.
 - Marchesini, G., Brizi, M., Bianchi, G., *et al.*, (2001) 'Nonalcoholic fatty liver disease: A feature of the metabolic syndrome', *Diabetes*, 50(8), pp. 1844–1850.
 - Mukherjee, S., Banerjee, A., Das, P. and Chatterjee, S. (2024) 'Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus', *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 18(1), pp. 102–109.
 - Saadeh, S., Younossi, Z.M., Remer, E.M., *et al.*, (2002) 'The utility of radiological imaging in nonalcoholic fatty liver disease', *Gastroenterology*, 123(3), pp. 745–750.
 - Sanyal, A.J., Friedman, S.L., McCullough, A.J. and Dimick-Santos, L. (2015) 'Challenges and opportunities in drug development for NASH', *Gastroenterology*, 148(7), pp. 1272–1281.
 - Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G. and Barbui, C. (2016) 'Non-alcoholic fatty liver disease and risk of cardiovascular disease', *Journal of Hepatology*, 65(3), pp. 589–600.
 - Wong, V.W.S., Adams, L.A., de Lédinghen, V., Wong, G.L.H. and Sookoian, S. (2018) 'Noninvasive biomarkers in NAFLD', *Gastroenterology*, 155(2), pp. 391–402.
 - Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) 'Global epidemiology of nonalcoholic fatty liver disease', *Hepatology*, 64(1), pp. 73–84.